As part of the U.S. Food and Drug Administration’s continued commitment to protect and promote the health of all women, the Center for Devices and Radiological Health (CDRH) is sharing its Health of Women Program Strategic Plan.
CDRH initially issued a proposed strategic plan in September 2019 and has considered public feedback to inform this strategic plan, which lays out the framework to further the FDA’s mission by protecting and promoting the health of women, strengthening regulatory science, and identifying and addressing current and emerging issues in medical device research and regulation for the health of all women.
As scientists and the medical community continue to learn more about sex and gender differences, they are learning that both sex—an individual’s biological characteristics—and gender—the social construct by which one may define oneself —may play significant roles in the course and outcome of conditions that affect all human organ systems. While sex and gender are interrelated, they are not necessarily mutually exclusive, and their interactions may affect physiological reactions, presentation of disease and treatment outcomes.
Now more than ever, we need to understand the implications sex and gender present for the performance of medical devices in all individuals. The CDRH Health of Women program is a comprehensive, collaborative, landmark program built on the premise that both sex and gender have a considerable impact on a woman’s overall health, not just their reproductive or sexual health. With patients at the heart of this initiative, and with the strategic plan as a blueprint for the center’s priorities, Health of Women intends to ensure all women have access to innovative, safe and effective medical devices.
A lack of representation can have serious consequences for health outcomes for women. An example of this is cardiovascular devices like pacemakers that may have different outcomes and complication rates in men and women. This is just one instance of when sex and gender make a difference in designing a clinical study that will provide optimal results for safety and effectiveness for all patients.
The strategic plan lays out the program’s three main priorities:
- Sex- and Gender-Specific Analysis & Reporting—Improve availability, analysis and communication of sex- and gender-specific information for the safe and effective use of medical devices to improve and better understand the performance of medical devices in women; optimize CDRH practices for consistent sex- and gender-specific data collection, analysis and reporting; ensure CDRH’s policies evolve with current science.
- Integrated Approach for Current & Emerging Issues Related to the Health of Women—Strengthen internal health science programs and initiatives across CDRH, working together with CDRH offices and their stakeholders, to create actions that aim to improve the overall health and quality of life for women; coordinate and lead an integrated approach to analyze current and emerging issues related to the health of women; explore innovative strategies, technologies and device-specific study paradigms; develop center-wide policies and outreach activities related to the health of women.
- Research Roadmap—Develop a guide for navigating the health of women medical device ecosystem; address identified gaps and unmet needs related to the health of women through targeted resources; promote advancement of regulatory science related to the health of women.
With the implementation of these three strategic priorities, the FDA aims to deepen their understanding of how medical devices work for women and continue their efforts to help assure that medical devices – those developed specifically for women, and those developed for all people – optimally align with the considerations of usability and performance in women. In this way, they hope to achieve the highest quality of innovation, safety and effectiveness for every patient.
